Five companies including SK Biopharm, accounting for 67% of total technology exports
It was found that five domestic pharmaceutical and bio companies that received government support last year achieved a technology export worth about 7 trillion won last year.
The Ministry of Health and Welfare announced on the 25th that the number of global technology exports by domestic pharmaceutical and bio companies supported by the Korea Health Industry Promotion Agency in 2020 was 6,800 billion won. This is an amount equivalent to 67% of the total contract amount for technology exports of 10,1492 trillion won in 2020 announced by the Pharmaceutical and Bio Association in December of last year.
In particular, bio-venture companies such as Alteogen, Voronoi, and Legochem Bioscience accounted for 84% of the total exports. This is evaluated as an open innovation in which global pharmaceutical companies receive technology transfer and develop original technology and new drug candidates developed by bio-venture companies.
Alteogen’s ALT-B4 is a human recombinant hyaluronic acid degradation factor that can replace the formulation of intravenous antibodies and protein drugs with subcutaneous drugs. This was developed through self-developed subcutaneous injection formulation modification platform technology, and additional technology exports are expected in the future.
Pandemic Corporation’s YH12852 is a gastrointestinal tract disease treatment. After successfully completing preclinical toxicity and phase 1 clinical trials in Korea, the technology is transferred to the United States, and a phase 2 clinical trial is planned in the United States this year.
SK Biopharm’s Cenovamate is Korea’s first anti-epileptic drug and has independently carried out the entire process from discovery of candidate substances to global clinical development and marketing approval. It is expected to achieve the nation’s first global blockbuster drug (sales of more than 1 trillion won) with the recent achievements in technology transfer of up to 5788 billion won to Japan.
Voronoi’s VRN07 is a new drug that can selectively act on non-small cell lung cancer caused by gene mutation, and is expected to be an effective treatment method for mutant non-small cell lung cancer and solid cancer patients suffering from general chemotherapy.
Legochem Bioscience’s LCB67 is a new drug candidate that selectively acts on cell lung cancer, liver cancer, and various solid cancers.
Hyeon Soo-yop, a high-tech medical support officer at the Ministry of Welfare and Welfare, said, “We have achieved the highest technology export performance ever through the voluntary R&D and bold investments of private companies.” We plan to further strengthen our full-cycle support through this program.”
Copyright owner © Doctor Shinmun Unauthorized reproduction and redistribution prohibited